Literature DB >> 11358831

TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.

M S Greenblatt1, P O Chappuis, J P Bond, N Hamel, W D Foulkes.   

Abstract

Several groups have studied the molecular pathology of inherited breast cancer. By combining several such studies, we show in this study that somatic TP53 abnormalities are more common in breast cancer associated with BRCA1 or BRCA2 germ-line mutations than in sporadic breast cancers (odds ratio, 2.8; P = 0.0003). Then, we compared the spectrum of TP53 mutations for breast cancers in the IARC TP53 mutation database with the 82 mutations reported in BRCA1/2-associated breast cancers. The spectrum differed significantly both in distribution (P < 1 x 10(-6)) and in base changes (P = 0.025). Mutations at A:T bp were more common in BRCA1/2-associated tumors and strand bias suggesting DNA repair abnormalities was found. Changes were common at TP53 codons that are not mutation hotspots. Structural modeling showed that most of these p53 non-hotspot amino acids characterized in breast tumors isolated from patients with deficient BRCA1/2 function are distributed in a region of the protein on the opposite side of the p53 DNA-binding surface. Our results suggest that BRCA1/2 mutations influence the type and distribution of TP53 mutations seen in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358831

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  62 in total

1.  Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity.

Authors:  Michael A Resnick; Alberto Inga
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-08       Impact factor: 11.205

2.  Mapping the physical and functional interactions between the tumor suppressors p53 and BRCA2.

Authors:  Sridharan Rajagopalan; Antonina Andreeva; Trevor J Rutherford; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-26       Impact factor: 11.205

3.  Correcting errors in the BRCA1 warning system.

Authors:  Yanping Liang; William J Dearnaley; Nick A Alden; Maria J Solares; Brian L Gilmore; Kevin J Pridham; A Cameron Varano; Zhi Sheng; Elizabeth Alli; Deborah F Kelly
Journal:  DNA Repair (Amst)       Date:  2018-11-22

4.  Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer.

Authors:  Yanying Huo; Hong Cai; Irina Teplova; Christian Bowman-Colin; Guanghua Chen; Sandy Price; Nicola Barnard; Shridar Ganesan; Vassiliki Karantza; Eileen White; Bing Xia
Journal:  Cancer Discov       Date:  2013-05-06       Impact factor: 39.397

5.  Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy.

Authors:  Tadeusz Majewski; Sangkyou Lee; Joon Jeong; Dong-Sup Yoon; Andrzej Kram; Mi-Sook Kim; Tomasz Tuziak; Jolanta Bondaruk; Sooyong Lee; Weon-Seo Park; Kuang S Tang; Woonbok Chung; Lanlan Shen; Saira S Ahmed; Dennis A Johnston; H Barton Grossman; Colin P Dinney; Jain-Hua Zhou; R Alan Harris; Carrie Snyder; Slawomir Filipek; Steven A Narod; Patrice Watson; Henry T Lynch; Adi Gazdar; Menashe Bar-Eli; Xifeng F Wu; David J McConkey; Keith Baggerly; Jean-Pierre Issa; William F Benedict; Steven E Scherer; Bogdan Czerniak
Journal:  Lab Invest       Date:  2008-05-05       Impact factor: 5.662

Review 6.  The expanding universe of p53 targets.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

7.  Germline mutations and polymorphisms in the origins of cancers in women.

Authors:  Kim M Hirshfield; Timothy R Rebbeck; Arnold J Levine
Journal:  J Oncol       Date:  2010-01-10       Impact factor: 4.375

Review 8.  Preclinical mouse models for BRCA1-associated breast cancer.

Authors:  R M Drost; J Jonkers
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640

9.  The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Authors:  O M Sinilnikova; A C Antoniou; J Simard; S Healey; M Léoné; D Sinnett; A B Spurdle; J Beesley; X Chen; M H Greene; J T Loud; F Lejbkowicz; G Rennert; S Dishon; I L Andrulis; S M Domchek; K L Nathanson; S Manoukian; P Radice; I Konstantopoulou; I Blanco; A L Laborde; M Durán; A Osorio; J Benitez; U Hamann; F B L Hogervorst; T A M van Os; H J P Gille; S Peock; M Cook; C Luccarini; D G Evans; F Lalloo; R Eeles; G Pichert; R Davidson; T Cole; J Cook; J Paterson; C Brewer; D J Hughes; I Coupier; S Giraud; F Coulet; C Colas; F Soubrier; E Rouleau; I Bièche; R Lidereau; L Demange; C Nogues; H T Lynch; R K Schmutzler; B Versmold; C Engel; A Meindl; N Arnold; C Sutter; H Deissler; D Schaefer; U G Froster; K Aittomäki; H Nevanlinna; L McGuffog; D F Easton; G Chenevix-Trench; D Stoppa-Lyonnet
Journal:  Br J Cancer       Date:  2009-08-25       Impact factor: 7.640

10.  Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.

Authors:  Elizabeth M Swisher; Rachel M Gonzalez; Toshiyasu Taniguchi; Rochelle L Garcia; Tom Walsh; Barbara A Goff; Piri Welcsh
Journal:  Mol Cancer       Date:  2009-07-14       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.